These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 2072144)

  • 1. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
    Falkson CI; Falkson G; Falkson HC
    J Clin Oncol; 1991 Aug; 9(8):1403-8. PubMed ID: 2072144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
    Falkson CI; Ibrahim J; Kirkwood JM; Coates AS; Atkins MB; Blum RH
    J Clin Oncol; 1998 May; 16(5):1743-51. PubMed ID: 9586887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
    Falkson CI
    Med Oncol; 1995 Mar; 12(1):35-40. PubMed ID: 8542245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
    Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
    J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
    J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
    Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
    J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
    Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W
    J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
    Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Seipp CA; Einhorn JH; White DE; Steinberg SM
    J Clin Oncol; 1999 Mar; 17(3):968-75. PubMed ID: 10071291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T
    J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
    Kaufmann R; Spieth K; Leiter U; Mauch C; von den Driesch P; Vogt T; Linse R; Tilgen W; Schadendorf D; Becker JC; Sebastian G; Krengel S; Kretschmer L; Garbe C; Dummer R;
    J Clin Oncol; 2005 Dec; 23(35):9001-7. PubMed ID: 16260697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
    Sertoli MR; Queirolo P; Bajetta E; Del Vecchio M; Comella G; Barduagni L; Bernengo MG; Vecchio S; Criscuolo D; Bufalino R; Morabito A; Cascinelli N
    Melanoma Res; 1999 Oct; 9(5):503-9. PubMed ID: 10596917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
    Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
    Andersson R; Ake Hofer P; Riklund-Ahlström K; Henriksson R
    Melanoma Res; 2003 Feb; 13(1):87-91. PubMed ID: 12569290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
    Young AM; Marsden J; Goodman A; Burton A; Dunn JA
    Clin Oncol (R Coll Radiol); 2001; 13(6):458-65. PubMed ID: 11824887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z; Strojan P
    Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine.
    Gröhn P; Kumpulainen E; Nuortio L; Hakala T; Vuoristo MS; Korpela M; Heikkinen M; Salmi R; Jakobsson M; Numminen S
    Eur J Cancer; 1992; 28(2-3):441-3. PubMed ID: 1591060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
    Thomson DB; Adena M; McLeod GR; Hersey P; Gill PG; Coates AS; Olver IN; Kefford RF; Lowenthal RM; Beadle GF
    Melanoma Res; 1993 Apr; 3(2):133-8. PubMed ID: 8518552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.